

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Effipro duo 134 mg/40 mg spot-on solution for medium dogs (AT, BE, BG, CZ, DE, EE, EL, ES, FR, HU, IE, IT LV, LT, NL, PL, PT, RO, SK)

Effipro comp 134 mg/40 mg spot-on solution for medium dogs (DK, NO, SE)

Fipronil Pyriproxyfen Virbac 134 mg/40 mg spot-on solution for medium dogs (UK/NI)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 1.34 ml pipette contains:

Active substances:

Fipronil 134.0 mg

Pyriproxyfen 40.2 mg

Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Butylhydroxyanisole E320	0.268 mg
Butylhydroxytoluene E321	0.134 mg
Diethylene glycol monoethyl ether	

Clear, colourless to yellowish solution.

3. CLINICAL INFORMATION

3.1 Target species

Dogs (10-20 kg)

3.2 Indications for use for each target species

To be used against infestations with fleas alone or in association with ticks.

Against fleas:

Treatment and prevention of infestations by fleas (*Ctenocephalides felis*). One treatment prevents further infestations for 7 weeks.

Prevention of the multiplication of fleas by preventing flea eggs developing into adult fleas for 12 weeks after application.

The veterinary medicinal product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD) where this has been previously diagnosed by a veterinary surgeon.

Against ticks:

Treatment of infestations by ticks (*Ixodes ricinus*).

One treatment provides persistent acaricidal efficacy for 2 weeks against *Ixodes ricinus*, and for 4 weeks against *Dermacentor reticulatus* and *Rhipicephalus sanguineus*.

If ticks of some species (*Dermacentor reticulatus*, *Rhipicephalus sanguineus*) are present at the time of application, not all ticks may be killed within 48 hours.

3.3 Contraindications

Do not use in rabbits, as adverse reactions and even death could occur.

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

3.4 Special warnings

Shampooing or immersion of the animal in water directly after treatment may reduce the duration of activity. The veterinary medicinal product remains effective against fleas for 5 weeks when the dog is shampooed at monthly intervals after treatment. If the dog requires shampooing, it is better to do so before treatment.

Water immersion repeated on two occasions post treatment did not affect adulticidal efficacy against fleas nor the efficacy related to the prevention of the development of flea eggs into adult fleas.

The influence of water immersion or shampooing of the dog on the efficacy of the veterinary medicinal product against ticks has not been evaluated.

At the beginning of the control measures, in the case of an infestation, the animal's basket, bedding and regular resting areas such as carpets and soft furnishings should be treated, with a suitable insecticide and vacuumed regularly.

To reduce environmental flea challenge, all animals living in the same household should also be treated with a suitable flea control veterinary medicinal product.

The veterinary medicinal product does not prevent ticks from attaching to animals. Transmission of infectious disease by ticks cannot be completely excluded if conditions are unfavourable.

Immediate efficacy has been demonstrated against *Ixodes ricinus*, indicating that ticks of this species are likely to be killed within 48 hours of veterinary medicinal product application. If *Dermacentor reticulatus* or *Rhipicephalus sanguineus* ticks are present when the veterinary medicinal product is applied, these ticks may not be killed within the first 48 hours.

Once dead, ticks will often drop off the animal. Any remaining ticks should be carefully removed, ensuring that their mouth parts are not left within the skin.

3.5 Special precautions for use

Special precautions for safe use in the target species:

For external use only.

Animals should be weighed accurately prior to treatment.

In absence of safety data, the veterinary medicinal product should not be used in puppies less than 10 weeks old and/or weighing less than 2 kg.

Care should be taken to avoid the content of the pipette coming into contact with the eyes or mouth of the recipient dogs. In particular oral uptake due to the licking of the application site by treated or in-contact animals should be avoided.

Do not apply the veterinary medicinal product on wounds or damaged skin.

In the absence of additional safety studies, do not repeat the treatment at intervals of less than 4 weeks.

The use of the veterinary medicinal product has not been studied in sick and debilitated dogs.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

The veterinary medicinal product may cause neurotoxicity.

The veterinary medicinal product may be harmful if swallowed.

Avoid ingestion including hand to mouth contact.

Do not smoke, drink or eat during application.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

This veterinary medicinal product can cause eye and mucous membrane irritation.

Avoid contact with skin, eye and mouth, including hand to eye contact.

In the case of accidental skin or eye contact, immediately and thoroughly flush with water. If skin or eye irritation persists, seek medical advice and show the package leaflet or the label to the physician.

Wash hands after use.

Treated animals should not be handled until the application site is dry, and children should not be allowed to play with treated animals until the application site is dry. It is therefore recommended that animals are not treated during the day, but should be treated during the early evening, and that recently treated animals should not be allowed to sleep with owners, especially children.

Keep the pipettes in the original packaging until ready for use and dispose of used pipettes immediately.

Special precautions for the protection of the environment:

Not applicable.

Other precautions:

Fipronil and pyriproxyfen may adversely affect aquatic organisms. Dogs should be prevented from accessing streams and rivers for 48-hours following treatment (see also section 5.5).

The veterinary medicinal product may have adverse effects on painted, varnished or other household surfaces or furnishings. Allow the application site to dry before permitting contact with such materials.

3.6 Adverse events

Dogs

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Application site reaction ¹ (e.g. Application site skin squamosis, Application site alopecia, Application site pruritus, Application site erythema, Application site skin discolouration) Generalised itching, Alopecia Hypersalivation, Vomiting Neurological disorder ² (e.g. Hyperaesthesia, Central nervous system depression, Neurological symptoms) Respiratory signs
Undetermined frequency (Cannot be estimated from the available data)	Application site greasy fur ^{1,3} , Application site skin scaling ^{1,3,4}

¹Transient

²Reversible

³Cosmetic effect

⁴Slight

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder

or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

Laboratory studies using fipronil and pyriproxyfen have not shown any produced of teratogenic or embryotoxic effects.

The safety of the veterinary medicinal product has not been established in pregnant and lactating bitches.

Use in pregnant and lactating animals only according to the benefit-risk assessment by the responsible veterinarian.

3.8 Interaction with other medicinal products and other forms of interaction

None known.

3.9 Administration routes and dosage

Spot-on use.

Dosage:

Apply one pipette of 1.34 ml per dog for a dog weighing from 10 to 20 kg corresponding to the minimal recommended dose of 6.7 mg fipronil /kg b.w. and 2 mg pyriproxyfen/kg b.w.


Volume	Dog weight	Fipronil (mg)	Pyriproxyfen (mg)
0.67 ml	2-10 kg	67	20.1
1.34 ml	10-20 kg	134	40.2
2.68 ml	20-40 kg	268	80.4
4.02 ml	40-60 kg	402	120.6

For dogs over 60 kg the appropriate combination of pipettes should be used.


Method of administration:

Remove the pipette from the overblister. Hold the pipette upright. Tap the narrow part of the pipette to ensure that the contents are within the main body of the pipette. Break the snap-off top of the spot-on pipette along the scored line.

Part the pet's coat on base of the neck before the shoulder blades until the skin is visible. Place the tip of the pipette directly against the skin and squeeze gently several times to empty the contents. If necessary the contents of the pipette can be administered at one or two additional point(s) along the pet's back to avoid run-off or more superficial application to the hair coat, particularly in large dogs.



Drop stop system (the veterinary medicinal product is released only by pressing the body of the pipette).



One pipette provides a single treatment, with the possibility to repeat administrations on a monthly basis. For optimal control of flea and tick infestations and flea multiplication, the treatment schedule can be based on the local epidemiological situation.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

No serious adverse effects were observed in a safety study in 10-week old puppies treated with up to 5 times the maximum recommended dose 3 times at intervals of 4 weeks and with the maximum recommended dose 6 times at intervals of 4 weeks.

The risk of experiencing adverse events (see section 3.6) may however increase with overdosing, so animals should always be treated with correct pipette size according to bodyweight.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QP53AX65

4.2 Pharmacodynamics

Fipronil is an insecticide and acaricide belonging to the phenylpyrazole family. Fipronil and its metabolite fipronil sulfone act at ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA) as well as desensitising (D) and non-desensitising (N) channels gated by glutamate (Glu, unique invertebrate ligand-gated chloride channels), thereby blocking pre- and post-synaptic transfer of chloride ions across cell membranes. This results in uncontrolled activity of the central nervous system and death of insects or acarid.

Pyriproxyfen is an insect growth regulator (IGR) of the class of compounds known as juvenile hormone analogues. Pyriproxyfen sterilises adult fleas and inhibits the development of immature stages. The molecule prevents, by contact, the emergence of adult insects by blocking the development of eggs (ovicidal effect), larvae and pupae (larvicidal effect), which are subsequently eliminated. Following contact and/or ingestion by adult fleas, the molecule also acts by sterilising eggs during their maturation and before being laid. The molecule prevents contamination of the environment of treated animals with the immature stages of fleas

Combination of fipronil and pyriproxyfen provides an insecticidal and acaricidal activity against fleas (*Ctenocephalides felis*), ticks (*Rhipicephalus sanguineus*, *Dermacentor reticulatus*, *Ixodes ricinus*) in addition to preventing flea eggs developing into adult fleas.

4.3 Pharmacokinetics

Following topical application of the veterinary medicinal product to dogs, under the normal conditions of use, fipronil and pyriproxyfen, are well distributed across the haircoat of the dog by 24 hours.

The major metabolite of Fipronil is the sulfone derivative, which also possesses insecticidal and acaricidal properties.

The concentrations of fipronil, fipronil sulfone and pyriproxyfen in the haircoat decrease over time but are still detectable for at least 84 days after application.

After administration of the veterinary medicinal product, the plasmatic peak concentration is reached between 3 to 7 days for fipronil and between 7 to 14 days for fipronil sulfone. The plasmatic peak concentration of pyriproxyfen is reached between 1 to 3 days after administration. The plasmatic concentrations of fipronil and pyriproxyfen decrease over time and the concentrations are quantifiable up to 50 days after application.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

None known.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

5.3 Special precautions for storage

Do not store above 30°C.

Store in a dry place.

Keep the blister pack in the outer carton in order to protect from light.

5.4 Nature and composition of immediate packaging

Transparent multi-layer plastic single-dose pipettes containing 1.34 ml obtained by thermoforming a transparent bottom complex (polyacrylonitrile-methacrylate or polyethylene-ethylene vinyl alcohol-polyethylene), polypropylene, cyclic olefin copolymer, polypropylene) and closed by heat sealing with a lid complex (polyacrylonitrile-methacrylate or polyethylene-ethylene vinyl alcohol-polyethylene), aluminium, polyethylene-terephthalate).

The boxes contain individual pipette(s) placed in overblister(s) made from polypropylene, cyclic olefin copolymer, polypropylene and closed with lid made from polyethylene-terephthalate, aluminium, polypropylene.

Boxes of 1, 4, 24 and 60 pipettes (large boxes including envelopes intended for dispensing a reduced number of pipettes). [this sentence will be deleted in case the dispensing envelope cannot be accepted].

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

The veterinary medicinal product should not enter water courses as this may be dangerous for fish or other aquatic organisms.

Do not contaminate ponds, waterways or ditches with the veterinary medicinal product or empty container.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

VIRBAC

7. MARKETING AUTHORISATION NUMBER(S)

8. DATE OF FIRST AUTHORISATION

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription [AT, BE, CZ (24 or 60 pipettes), DE, DK, GR, HU, IE, NO, PL, PT, SE, UK/NI]

Veterinary medicinal product not subject to prescription [BG, CZ (1 or 4 pipettes), EE, ES, FR, IT, LT, LV, NL, RO, SK]

Detailed information on this veterinary medicinal product is available in the [Union Product Database](https://medicines.health.europa.eu/veterinary) (<https://medicines.health.europa.eu/veterinary>).

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Box containing 1 individual pipette placed in overblister
Box containing 4 individual pipettes placed in 2 overblisters
Box containing 24 individual pipettes placed in 12 overblisters
Box containing 60 individual pipettes placed in 30 overblisters



Fleas, Ticks, Flea eggs



1. NAME OF THE VETERINARY MEDICINAL PRODUCT


EFFIPRO DUO 134 mg/40 mg spot-on solution (AT, BE, BG, CZ, DE, EE, EL, ES, FR, HU, IE, IT LV, LT, NL, PL, PT, RO, SK)

EFFIPRO COMP 134 mg/40 mg spot-on solution (DK, NO, SE)

FIPRONIL PYRIPROXYFEN VIRBAC 134 mg/40 mg spot-on solution (UK/NI)

2. STATEMENT OF ACTIVE SUBSTANCES




Each pipette contains:

 [optional]	Fipronil	Pyriproxyfen
1.34 ml	134 mg	40.2 mg

3. PACKAGE SIZE



1 pipette
1.34 ml



4. TARGET SPECIES

Dogs 10-20 kg

5. INDICATIONS

For products not subject to veterinary prescription

To be used against infestations with fleas alone or in association with ticks.

6. ROUTES OF ADMINISTRATION

Spot-on use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE


Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

Do not store above 30°C.

Store in a dry place.

Keep the blister pack in the outer carton in order to protect from light.



10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.



11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.



[optional]

13. NAME OF THE MARKETING AUTHORISATION HOLDER

VIRBAC

14. MARKETING AUTHORISATION NUMBERS

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Dispensing envelope with a capacity of either one or two 2-pipette blister(s) (to be included in large boxes only)



Fleas, Ticks, Flea eggs



This intermediate package is intended to contain at least one 2-pipette blister (and up to two 2-pipette blisters).

1. NAME OF THE VETERINARY MEDICINAL PRODUCT


EFFIPRO DUO spot-on solution (AT, BE, BG, CZ, DE, EE, EL, ES, FR, HU, IE, IT LV, LT, NL, PL, PT, RO, SK)

EFFIPRO COMP spot-on solution (DK, NO, SE)

FIPRONIL PYRIPROXYFEN VIRBAC spot-on solution (UK/NI)

2. STATEMENT OF ACTIVE SUBSTANCES

Each pipette contains:

 [optional]	Dog	Fipronil	Pyriproxyfen
0.67 ml	2-10 kg	67 mg	20.1 mg
1.34 ml	10-20 kg	134 mg	40.2 mg
2.68 ml	20-40 kg	268 mg	80.4 mg
4.02 ml	40-60 kg	402 mg	120.6 mg

3. PACKAGE SIZE

This intermediate package is intended to contain at least one 2-pipette blister (and up to two 2-pipette blisters).

4. TARGET SPECIES

Dogs

5. INDICATIONS

For products not subject to veterinary prescription.

To be used against infestations with fleas alone or in association with ticks.

6. ROUTES OF ADMINISTRATION

Spot-on use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

For lot number and expiry date, please refer to the overblister or pipette.

9. SPECIAL STORAGE PRECAUTIONS

Do not store above 30°C.

Store in a dry place.

Keep the blister pack in the outer carton in order to protect from light.



30°C

[optional]

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.



11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.



[optional]

13. NAME OF THE MARKETING AUTHORISATION HOLDER

VIRBAC

14. MARKETING AUTHORISATION NUMBERS

15. BATCH NUMBER

For lot number and expiry date, please refer to the overblister or pipette.

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Overblister packed in 1 pipette blister or 2 pipette blisters divisible per pipette

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

EFFIPRO DUO (AT, BE, BG, CZ, DE, EE, EL, ES, FR, HU, IE, IT LV, LT, NL, PL, PT, RO, SK)
EFFIPRO COMP (DK, NO, SE)
FIPRONIL PYRIPROXYFEN VIRBAC (UK/NI)



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

134 mg/40 mg
10-20 kg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Individual Pipette

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

EFFIPRO DUO (AT, BE, BG, CZ, DE, EE, EL, ES, FR, HU, IE, IT LV, LT, NL, PL, PT, RO, SK)
EFFIPRO COMP (DK, NO, SE)
FIPRONIL PYRIPROXYFEN VIRBAC (UK/NI)



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

134 mg/40 mg
10-20 kg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

B. PACKAGE LEAFLET

PACKAGE LEAFLET:

1. Name of the veterinary medicinal product

Effipro duo 67 mg/20 mg spot-on solution for small dogs (AT, BE, BG, CZ, DE, EE, EL, ES, FR, HU, IE, IT LV, LT, NL, PL, PT, RO, SK)

Effipro duo 134 mg/40 mg spot-on solution for medium dogs (AT, BE, BG, CZ, DE, EE, EL, ES, FR, HU, IE, IT LV, LT, NL, PL, PT, RO, SK)

Effipro duo 268 mg/80 mg spot-on solution for large dogs (AT, BE, BG, CZ, DE, EE, EL, ES, FR, HU, IE, IT LV, LT, NL, PL, PT, RO, SK)

Effipro duo 402 mg/120 mg spot-on solution for very large dogs (AT, BE, BG, CZ, DE, EE, EL, ES, FR, HU, IE, IT LV, LT, NL, PL, PT, RO, SK)

Effipro comp 67 mg/20 mg spot-on solution for small dogs (DK, NO, SE)

Effipro comp 134 mg/40 mg spot-on solution for medium dogs (DK, NO, SE)

Effipro comp 268 mg/80 mg spot-on solution for large dogs (DK, NO, SE)

Effipro comp 402 mg/120 mg spot-on solution for very large dogs (DK, NO, SE)

Fipronil Pyriproxyfen Virbac 67 mg/20 mg spot-on solution for small dogs (UK/NI)

Fipronil Pyriproxyfen Virbac 134 mg/40 mg spot-on solution for medium dogs (UK/NI)

Fipronil Pyriproxyfen Virbac 268 mg/80 mg spot-on solution for large dogs (UK/NI)

Fipronil Pyriproxyfen Virbac 402 mg/120 mg spot-on solution for very large dogs (UK/NI)

2. Composition

Each pipette contains:	Active substances		Excipients	
	Fipronil	Pyriproxyfen	BHA	BHT
Pipette volume (single dose unit)				
0.67 ml	67 mg	20.1 mg	0.134 mg	0.067 mg
1.34 ml	134 mg	40.2 mg	0.268 mg	0.134 mg
2.68 ml	268 mg	80.4 mg	0.536 mg	0.268 mg
4.02 ml	402 mg	120.6 mg	0.804 mg	0.402 mg

Clear, colourless to yellowish solution.

3. Target species

Dogs

4. Indications for use

To be used against infestations with fleas alone or in association with ticks.

Against fleas:

Treatment and prevention of infestations by fleas (*Ctenocephalides felis*). One treatment prevents further infestations for 7 weeks.

Prevention of the multiplication of fleas preventing flea eggs developing into adult fleas for 12 weeks after application.

The veterinary medicinal product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD) where this has been previously diagnosed by a veterinary surgeon.

Against ticks:

Treatment of infestations by ticks (*Ixodes ricinus*).

One treatment provides persistent acaricidal efficacy for 2 weeks against *Ixodes ricinus*, and for 4 weeks against *Dermacentor reticulatus* and *Rhipicephalus sanguineus*.

If ticks of some species (*Dermacentor reticulatus*, *Rhipicephalus sanguineus*) are present at the time of application, not all ticks may be killed within 48 hours.

5. Contraindications

Do not use in rabbits, as adverse reactions and even death could occur.

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

6. Special warnings

Special warnings:

Shampooing or immersion of the animal in water directly after treatment may reduce the duration of activity. The veterinary medicinal product remains effective against fleas for 5 weeks when the dog is shampooed at monthly intervals after treatment. If the dog requires shampooing, it is better to do so before treatment.

Water immersion repeated on two occasions post treatment did not affect adulticidal efficacy against fleas nor the efficacy related to the prevention of the development of flea eggs into adult fleas.

The influence of water immersion or shampooing of the dog on the efficacy of the veterinary medicinal product against ticks has not been evaluated.

At the beginning of the control measures, in the case of an infestation, the animal's basket, bedding and regular resting areas such as carpets and soft furnishings should be treated, with a suitable insecticide and vacuumed regularly.

To reduce environmental flea challenge, all animals living in the same household should also be treated with a suitable flea control veterinary medicinal product.

The veterinary medicinal product does not prevent ticks from attaching to animals. Transmission of infectious disease by ticks cannot be completely excluded if conditions are unfavourable. Immediate efficacy has been demonstrated against *Ixodes ricinus*, indicating that ticks of this species are likely to be killed within 48 hours of veterinary medicinal product application. If *Dermacentor reticulatus* or *Rhipicephalus sanguineus* ticks are present when the veterinary medicinal product is applied, these ticks may not be killed within the first 48 hours.

Once dead, ticks will often drop off the animal. Any remaining ticks should be carefully removed, ensuring that their mouth parts are not left within the skin.

Special precautions for safe use in the target species:

For external use only.

Animals should be weighed accurately prior to treatment.

In absence of safety data, the veterinary medicinal product should not be used in puppies less than 10 weeks old and/or weighing less than 2 kg.

Care should be taken to avoid the content of the pipette coming into contact with the eyes or mouth of the recipient dogs. In particular oral uptake due to the licking of the application site by treated or in-contact animals should be avoided.

Do not apply the veterinary medicinal product on wounds or damaged skin.

In the absence of additional safety studies, do not repeat the treatment at intervals of less than 4 weeks.

The use of the veterinary medicinal product has not been studied in sick and debilitated dogs.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

The veterinary medicinal product may cause neurotoxicity.

The veterinary medicinal product may be harmful if swallowed.

Avoid ingestion including hand to mouth contact.

Do not smoke, drink or eat during application.

In the event of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

This veterinary medicinal product can cause eye and mucous membrane irritation.

Avoid contact with skin, eye and mouth, including hand to eye contact.

In the case of accidental skin or eye contact, immediately and thoroughly flush with water. If skin or eye irritation persists, seek medical advice and show the package leaflet or the label to the physician.

Wash hands after use.

Treated animals should not be handled until the application site is dry, and children should not be allowed to play with treated animals until the application site is dry. It is therefore recommended that animals are not treated during the day, but should be treated during the early evening, and that recently treated animals should not be allowed to sleep with owners, especially children.

Keep the pipettes in the original packaging until ready for use and dispose of used pipettes immediately.

For animal treatment only.

Other precautions:

Fipronil and pyriproxyfen may adversely affect aquatic organisms. Dogs should be prevented from accessing streams and rivers for 48-hours following treatment.

The veterinary medicinal product may have adverse effects on painted, varnished or other household surfaces or furnishings. Allow the application site to dry before permitting contact with such materials.

Pregnancy and lactation:

Laboratory studies using fipronil and pyriproxyfen have not shown any produced of teratogenic or embryotoxic effects.

The safety of the veterinary medicinal product has not been established in pregnant and lactating bitches.

Use in pregnant and lactating animals only according to the benefit-risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

None known.

Overdose:

No serious adverse effects were observed in a safety study in 10-week old puppies treated with up to 5 times the maximum recommended dose 3 times at intervals of 4 weeks and with the maximum recommended dose 6 times at intervals of 4 weeks.

The risk of experiencing adverse reactions (see adverse events section) may however increase with overdosing, so animals should always be treated with correct pipette size according to bodyweight.

Major incompatibilities:

None known.

7. Adverse events

Dogs

Very rare (<1 animal / 10,000 animals treated, including isolated reports):
Application site reaction ¹ (e.g., Application site skin squamosis, Application site alopecia, Application site pruritus (itching), Application site erythema (redness), Application site skin discolouration)
Generalised itching, Alopecia (hair loss)
Hypersalivation, Vomiting
Neurological disorder ² (e.g. Hyperaesthesia (increased sensitivity to stimuli), Central nervous system depression, Neurological symptoms)
Respiratory signs
Undetermined frequency (Cannot be estimated from the available data)
Application site greasy fur ^{1,3} , Application site skin scaling ^{1,3,4}

¹Transient

²Reversible

³Cosmetic effect

⁴Slight

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}

8. Dosage for each species, routes and method of administration

Dosage:


Dog weight	Pipette volume (single dose unit)	Fipronil (mg)	Pyriproxyfen (mg)
2-10 kg	0.67 ml	67	20.1
10-20 kg	1.34 ml	134	40.2
20-40 kg	2.68 ml	268	80.4
40-60 kg	4.02 ml	402	120.6

For dogs over 60 kg the appropriate combination of pipettes should be used.


Method of administration:

Remove the pipette from the overblister. Hold the pipette upright. Tap the narrow part of the pipette to ensure that the contents are within the main body of the pipette. Break the snap-off top of the spot-on pipette along the scored line.

Part the pet's coat on base of the neck before the shoulder blades until the skin is visible. Place the tip of the pipette directly against the skin and squeeze gently several times to empty the contents. If necessary the contents of the pipette can be administered at one or two additional point(s) along the pet's back to avoid run-off or more superficial application to the hair coat, particularly in large dogs.



Drop stop system (the veterinary medicinal product is released only by pressing the body of the pipette).



9. Advice on correct administration

One pipette provides a single treatment, with the possibility to repeat administrations on a monthly basis. For optimal control of flea and tick infestations and flea multiplication, the treatment schedule can be based on the local epidemiological situation.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Do not store above 30°C.

Store in a dry place.

Keep the blister pack in the outer carton in order to protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and label after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

The veterinary medicinal product should not enter water courses as this may be dangerous for fish or other aquatic organisms.

Do not contaminate ponds, waterways or ditches with the veterinary medicinal product or empty container

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems.

These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription [AT, BE, CZ (24 or 60 pipettes), DE, DK, GR, HU, IE, NO, PL, PT, SE, UK/NL]

Veterinary medicinal product not subject to prescription [BG, CZ (1 or 4 pipettes), EE, ES, FR, IT, LT, LV, NL, RO, SK]

14. Marketing authorisation numbers and pack sizes

Boxes of 1, 4, 24 and 60 pipettes (large boxes including envelopes intended for dispensing a reduced number of pipettes). [this sentence will be deleted in case the dispensing envelope cannot be accepted].

Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

16. Contact details

Marketing authorisation holder and manufacturer responsible for batch release and contact details to report suspected adverse reactions:

VIRBAC
1^{ère} avenue 2065m LID
06516 Carros
France

Local representatives and contact details to report suspected adverse reactions:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information

Pyriproxyfen is an insect growth regulator (IGR) of the class of compounds known as juvenile hormone analogues. It prevents, by contact, the emergence of adult insects by blocking the development of eggs (ovicidal effect), larvae and pupae (larvicidal effect), which are subsequently eliminated.

Combination of fipronil and pyriproxyfen provides an insecticidal and acaricidal activity against fleas (*Ctenocephalides felis*), ticks (*Rhipicephalus sanguineus*, *Dermacentor reticulatus*, *Ixodes ricinus*) in addition to preventing flea eggs developing into adult fleas.

--